Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 06/05/2025 at 15:30

S&P Capital IQ

+0.59%

Evotec SE reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was EUR 199.98 million compared to EUR 208.73 million a year ago. Sales was EUR 199.98 million compared to EUR 208.73 million a year ago.

Net loss was EUR 31.58 million compared to EUR 20.67 million a year ago. Net loss was EUR 31.58 million compared to EUR 20.67 million a year ago. Basic loss per share from continuing operations was EUR 0.18 compared to EUR 0.12 a year ago.

Basic loss per share from continuing operations was EUR 0.18 compared to EUR 0.12 a year ago.

Latest news about Evotec SE

EVOTEC : Deutsche Bank reiterates its Neutral rating	09/07	ZD
EVOTEC : Warburg Research remains its Buy rating	26/06	ZD
Sector Update: Health Care Stocks Mixed Premarket Wednesday	25/06	MT
Evotec Joins Acute Kidney Injury Consortium	25/06	MT
Evotec SE Joins the NURTuRE-AKI Consortium for Establishing Patient Cohort for Establishing A Patient Cohort for Establishing a Patient Cohort for Acute Kidney Injury	25/06	CI
Evotec SE, Q1 2025 Earnings Call, May 06, 2025	20/06
EVOTEC : Warburg Research reiterates its Buy rating	17/06	ZD
Evotec SE Approves Board Appointments	03/06	CI
Evotec corrects recent rise – chart uninspiring	27/05	DP
Evotec recovers to March level	23/05	DP
EVOTEC : RBC reiterates its Buy rating	15/05	ZD
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins and Advance Small-Molecule Therapeutics at Scale	08/05	CI
EVOTEC : Deutsche Bank gives a Neutral rating	07/05	ZD
Evotec Secures New Grant to Develop Tuberculosis Treatments	07/05	MT
Evotec Receives $2.5 Mln Grant For Tb Treatments	07/05	RE
EVOTEC : Warburg Research keeps its Buy rating	06/05	ZD
Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2025	06/05	CI
Evotec starts the year with a decline in sales – shares lose significant ground	06/05	DP
RBC leaves Evotec at 'Outperform' - target €11.60	06/05	DP
Evotec very weak after quarterly figures	06/05	DP
EVOTEC : Receives a Buy rating from RBC	06/05	ZD
Evotec Outlook FY Revenue EUR 840-880 Million	06/05	RE
Evotec's Ongoing Bristol Myers Collaboration Triggers $75 Million Payments	24/04	MT
Evotec recovery stalls despite success in research alliance	24/04	DP
Evotec Announces Progress In Protein Degradation Collaboration With Bristol Myers Squibb	24/04	RE